RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 yearsShun Lu,Jie Wang,Yan Yu,Xinmin Yu,Yanping Hu,Zhiyong Ma,Xingya Li, Wu Zhuang,Yunpeng Liu,Weidong Li,Jiuwei Cui,Dong Wang,Wangjun Liao,Mengzhao Wang,Jianying Zhou,Zhehai Wang,Yuping Sun, Wanyu He, Yuanyuan BaoCANCER RESEARCH（2022）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
